-
Mashup Score: 0
AbstractAims. Hyperkalaemia frequently leads to interruption and discontinuation of neurohormonal antagonists, which may worsen heart failure prognosis. Some st
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure - 2 year(s) ago
This editorial refers to ‘Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled’, by J.P. Ferreira et al., https://doi.org/10.1093
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 26Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure - 2 year(s) ago
This editorial refers to ‘Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled’, by J.P. Ferreira et al., https://doi.org/10.1093
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Serum Potassium As A Predictor Of Adverse Clinical Outcomes In Patients With Increasing Comorbidity Burden - 3 year(s) ago
AbstractAims. The aim of this study was to establish whether patients with multiple comorbidities may be at elevated risk of hyperkalaemia (HK), a potentially l
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Potassium binders for chronic hyperkalaemia in people with chronic kidney disease - Natale, P - 2020 | Cochrane Library - 4 year(s) ago
Cochrane Database of Systematic Reviews Collapse all Expand all Background Hyperkalaemia is a common electrolyte abnormality caused by reduced renal potassium excretion in patients with chronic kidney diseases (CKD). Potassium binders, such as sodium polystyrene sulfonate and calcium polystyrene sulfonate, are widely used but may lead to constipation and other adverse gastrointestinal…
Source: www.cochranelibrary.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
Empagliflozin reduces the incidence of #hyperkalaemia, without significant increase in hypokalaemia, in patients with #HeartFailure across the full range of ejection fraction https://t.co/Ev59NQesfv #EHJ #ESCYoung @ehj_ed @rladeiraslopes https://t.co/FVhYbJlU7v